LOU/M |
post-treatment survival time from drug-treated IgM immunocytoma |
rat IgM immunocytoma cells (1 x 10E4 cells) then spiroplatin (8 mg/kg) (for 49 days) |
de Jong WH, etal., Cancer Res. 1983 Oct;43(10):4927-34. |
life span trait |
both |
154 days-193 days |
7 |
32.0 |
d |
0.38 |
1.0 |
necropsy |
0.0 |
0 |
post-treatment survival time from drug-treated IgM immunocytoma (CMO:0003867) |
109471 |
3146 |
LOU/M |
time from start of drug therapy to immunocytoma regrowth |
rat IgM immunocytoma cells (1 x 10E4 cells) then spiroplatin (2 mg/kg) (for 28 days) |
de Jong WH, etal., Cancer Res. 1983 Oct;43(10):4927-34. |
hypodermis integrity trait |
both |
154 days-193 days |
0 |
26.1 |
d |
|
7.1 |
in vivo caliper method |
0.0 |
0 |
Experiment 1 |
109486 |
3146 |
LOU/M |
maximum tumor size decrease to pretreatment tumor size ratio |
rat IgM immunocytoma cells (1 x 10E4 cells) then spiroplatin (1 mg/kg) (for 21 days) |
de Jong WH, etal., Cancer Res. 1983 Oct;43(10):4927-34. |
hypodermis integrity trait |
both |
154 days-193 days |
0 |
90.8 |
% |
|
12.7 |
in vivo caliper method |
0.0 |
0 |
Experiment 1 |
109482 |
3146 |
LOU/M |
maximum tumor size decrease to pretreatment tumor size ratio |
rat IgM immunocytoma cells (1 x 10E4 cells) then spiroplatin (0.25 mg/kg) (for 21 days) |
de Jong WH, etal., Cancer Res. 1983 Oct;43(10):4927-34. |
hypodermis integrity trait |
both |
154 days-193 days |
0 |
-2.5 |
% |
|
15.9 |
in vivo caliper method |
0.0 |
0 |
Experiment 2 |
109490 |
3146 |
LOU/M |
maximum tumor size decrease to pretreatment tumor size ratio |
rat IgM immunocytoma cells (1 x 10E4 cells) then spiroplatin (2 mg/kg) (for 21 days) |
de Jong WH, etal., Cancer Res. 1983 Oct;43(10):4927-34. |
hypodermis integrity trait |
both |
154 days-193 days |
0 |
78.5 |
% |
|
16.7 |
in vivo caliper method |
0.0 |
0 |
Experiment 1 |
109483 |
3146 |
LOU/M |
maximum tumor size decrease to pretreatment tumor size ratio |
rat IgM immunocytoma cells (1 x 10E4 cells) then spiroplatin (0.5 mg/kg) (for 21 days) |
de Jong WH, etal., Cancer Res. 1983 Oct;43(10):4927-34. |
hypodermis integrity trait |
both |
154 days-193 days |
0 |
63.6 |
% |
|
31.2 |
in vivo caliper method |
0.0 |
0 |
Experiment 2 |
109491 |
3146 |
LOU/M |
maximum tumor size decrease to pretreatment tumor size ratio |
rat IgM immunocytoma cells (1 x 10E4 cells) then spiroplatin (1 mg/kg) (for 21 days) |
de Jong WH, etal., Cancer Res. 1983 Oct;43(10):4927-34. |
hypodermis integrity trait |
both |
154 days-193 days |
0 |
95.8 |
% |
|
9.4 |
in vivo caliper method |
0.0 |
0 |
Experiment 2 |
109492 |
3146 |
LOU/M |
time from start of drug therapy to immunocytoma regrowth |
rat IgM immunocytoma cells (1 x 10E4 cells) then spiroplatin (1 mg/kg) (for 28 days) |
de Jong WH, etal., Cancer Res. 1983 Oct;43(10):4927-34. |
hypodermis integrity trait |
both |
154 days-193 days |
0 |
28.0 |
d |
|
8.7 |
in vivo caliper method |
0.0 |
0 |
Experiment 1 |
109485 |
3146 |
LOU/M |
time from start of drug therapy to immunocytoma regrowth |
rat IgM immunocytoma cells (1 x 10E4 cells) then spiroplatin (1 mg/kg) (for 21 days) |
de Jong WH, etal., Cancer Res. 1983 Oct;43(10):4927-34. |
hypodermis integrity trait |
both |
154 days-193 days |
0 |
20.2 |
d |
|
5.2 |
in vivo caliper method |
0.0 |
0 |
Experiment 2 |
109496 |
3146 |
LOU/M |
time from therapy-induced maximal immunocytoma size decrease to regrowth of tumor to a diameter of 10 mm |
rat IgM immunocytoma cells (1 x 10E4 cells) then spiroplatin (1 mg/kg) (for 7 days) |
de Jong WH, etal., Cancer Res. 1983 Oct;43(10):4927-34. |
hypodermis integrity trait |
both |
154 days-193 days |
0 |
7.2 |
d |
|
4.1 |
in vivo caliper method |
0.0 |
0 |
Experiment 2 |
109500 |
3146 |
LOU/M |
post-treatment survival time from drug-treated IgM immunocytoma |
rat IgM immunocytoma cells (1 x 10E4 cells) then spiroplatin (16 mg/kg) (for 28 days) |
de Jong WH, etal., Cancer Res. 1983 Oct;43(10):4927-34. |
life span trait |
both |
154 days-193 days |
5 |
26.0 |
d |
0.89 |
2.0 |
necropsy |
0.0 |
0 |
post-treatment survival time from drug-treated IgM immunocytoma (CMO:0003867) |
109470 |
3146 |
LOU/M |
post-treatment survival time from drug-treated IgM immunocytoma |
rat IgM immunocytoma cells (1 x 10E4 cells) then spiroplatin (4 mg/kg) (for 49 days) |
de Jong WH, etal., Cancer Res. 1983 Oct;43(10):4927-34. |
life span trait |
both |
154 days-193 days |
7 |
35.0 |
d |
0.76 |
2.0 |
necropsy |
0.0 |
0 |
post-treatment survival time from drug-treated IgM immunocytoma (CMO:0003867) |
109472 |
3146 |
LOU/M |
time from start of drug therapy to immunocytoma regrowth |
rat IgM immunocytoma cells (1 x 10E4 cells) then spiroplatin (0.5 mg/kg) (for 21 days) |
de Jong WH, etal., Cancer Res. 1983 Oct;43(10):4927-34. |
hypodermis integrity trait |
both |
154 days-193 days |
0 |
19.4 |
d |
|
2.2 |
in vivo caliper method |
0.0 |
0 |
Experiment 2 |
109495 |
3146 |
LOU/M |
time from therapy-induced maximal immunocytoma size decrease to regrowth of tumor to a diameter of 10 mm |
rat IgM immunocytoma cells (1 x 10E4 cells) then spiroplatin (0.5 mg/kg) (for 7 days) |
de Jong WH, etal., Cancer Res. 1983 Oct;43(10):4927-34. |
hypodermis integrity trait |
both |
154 days-193 days |
0 |
6.8 |
d |
|
3.6 |
in vivo caliper method |
0.0 |
0 |
Experiment 2 |
109499 |
3146 |